Navigation Links
Also in the July 29 JNCI
Date:7/29/2008

The Same Dose of Anthracycline Is Not Safe for Everyone

Not all patients can tolerate the currently recommended cumulative dose of epirubicin. New models can help physicians calculate the epirubicin dose associated with a 5 percent risk of cardiotoxicity for individual patients.

Oncologists frequently use anthracyclines, including epirubicin and doxorubicin, to treat breast cancer patients. However, the drugs cause lasting heart problems in a substantial number of patients. To limit the problem, current treatment guidelines suggest that patients receive no more than 900 mg/m2 epirubicin over the course of their cancer care.

In the current study, Marianne Ryberg, M.D., of the University of Copenhagen and colleagues followed 1,097 patients with metastatic breast cancer who were treated in a single hospital near Copenhagen between 1983 and 2003. The researchers assessed patients' risk factors for cardiotoxicity and corrected for the risk of death from all other competing causes of death, including cancer. (The studies that have previously concluded that the upper safe limit of epirubicin is 900 mg/m2 have not generally corrected for other causes of death.) Using these data, they calculated the maximum cumulative dose of epirubicin that is associated with a 5 percent risk of developing heart disease.

Ryberg and colleagues found that patient age, predisposition to heart disease, previous chest irradiation, and prior hormonal cancer therapy were associated with an individual's risk of developing heart problems following epirubicin treatment. By contrast, the researchers found that treatment with less epirubicin, a higher tumor burden, prior chemotherapy, and older age of the patient were associated with an increased risk of death from other, non-cardiac, causes.

Based on these data, the researchers lowered the cumulative dose recommended for most patients, with maximum doses ranging from 300 mg/m2 to 900 mg/m2. "
'/>"/>

Contact: Liz Savage
elizabeth.savage@oxfordjournals.org
301-841-1287
Journal of the National Cancer Institute
Source:Eurekalert

Page: 1 2 3 4 5

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Auckland, NZ (PRWEB) August 29, 2014 ... of Greg Allen to Chief Executive Officer effective from ... Chief Technology Officer for Winscribe. , “During this time ... Winscribe than Greg Allen,” said Matthew Weavers, Winscribe’s Founder ... leader with a wealth of commercial, IT and management ...
(Date:8/28/2014)... 2014 Career Step, an online provider ... new video designed to help students and career seekers ... billing field. The video details what medical coders and ... professionals, and the education requirements for entering this field. ... often overlooked when people are considering a career in ...
(Date:8/28/2014)... FL (PRWEB) August 29, 2014 ... that brings pharmaceutical industry precision to the development ... zoning approval for its primary location in Sarasota ... and decisively with a total commitment to attracting ... forward to creating," says David Wright, President and ...
(Date:8/28/2014)... When David Gergen, President of ... Mark Brnovich, was asked to publicly support Mr. Brnovich ... Attorney General seat in the State of Arizona, Mr. ... of Cardinal Hall of Fame wide receiver Roy Green ... Mark Walczak. Green, Kennard and Walczak are members of ...
(Date:8/28/2014)... Farmington, New York (PRWEB) August 29, 2014 ... Autumn as they will be traveling around the country ... with a final show in November. The New Energy ... exhibit sharing their timber frame design and build expertise, ... addition, Drake Ambrosino , New Energy Works’ Mid-West ...
Breaking Medicine News(10 mins):Health News:Winscribe Names Greg Allen as CEO 2Health News:Career Step Releases New Video Designed to Help Students Explore the Medical Coding and Billing Field 2Health News:Sarasota County Approves Zoning for Leading Medical Cannabis Firm AltMed 2Health News:Pro Player Health Alliance Back in the Political Arena 2Health News:Pro Player Health Alliance Back in the Political Arena 3Health News:New Energy Works Timberframers Prepares to Exhibit Timber Framing at Autumn Trade Shows 2Health News:New Energy Works Timberframers Prepares to Exhibit Timber Framing at Autumn Trade Shows 3
... ... recent launch of accounts on the popular social networking sites, Facebook, Twitter, and LinkedIn. ... Las Vegas, ... consultations, diagnoses, prescriptions, and doctors, excuses for work and school, expands its outreach to ...
... SEATTLE, Aug. 27 IDRI (Infectious Disease Research ... in Sudan to test its leishmaniasis vaccine candidate for ... complication of visceral leishmaniasis (VL) which is observed in ... predominantly affecting children. This trial reflects IDRI,s commitment to ...
... PRINCETON, N.J., Aug. 27 More than 160 ... are coming together at educational summits sponsored this fall by ... Continuing Education (CBCE). For the fifth year, the Inhibitor Education ... professionals and fellow patients to address pertinent topics such as ...
... rates similar to those with deceased donor transplant organs, ... People with kidney disease may do just as well ... from a deceased donor, new research has found. , ... 1,239 patients who had either received a kidney transplant ...
... Japan, Aug. 27 Hisamitsu Pharmaceutical Co., Inc. (TSE: ... completion of the tender offer for all outstanding shares of Noven ... price per share of $16.50. The subsequent offering period expired ... 2009 and was not extended. , , ...
... , MAPLE GROVE, Minn., Aug. 27 NeuroVasx, Inc., ... hemorrhagic and ischemic stroke, announced today that it has received approval ... Canada,s Therapeutic Products Directorate. In addition to Canadian regulatory approval, ... , Eric B. Timko, President and Chief Executive ...
Cached Medicine News:Health News:KoolDocs.com Increases Online Presence through Social Networking Premium Online Medical Consultation Service Now on Facebook, Twitter, and LinkedIn 2Health News:IDRI Initiates Therapeutic Vaccine Clinical Trial in Sudan Against Leishmaniasis 2Health News:IDRI Initiates Therapeutic Vaccine Clinical Trial in Sudan Against Leishmaniasis 3Health News:Patient Education Summits to Address Special Challenges of Hemophilia Patients and Their Families 2Health News:Patient Education Summits to Address Special Challenges of Hemophilia Patients and Their Families 3Health News:Patient Education Summits to Address Special Challenges of Hemophilia Patients and Their Families 4Health News:Home Dialysis a Good Option for Kidney Disease Patients 2Health News:Hisamitsu Pharmaceutical Announces Expiration of Subsequent Offering Period and Completion of Tender Offer for Outstanding Shares of Noven Pharmaceuticals 2Health News:NeuroVasx Receives Canadian Approval for cPAX Aneurysm Treatment System 2Health News:NeuroVasx Receives Canadian Approval for cPAX Aneurysm Treatment System 3
(Date:8/28/2014)... Calif. , Aug. 28, 2014  In anticipation of ... infographic is being made available for the first time. ... Diego offers a snapshot of ... Highlighting everything from the latest employment statistics to ... made San Diego such a vital ...
(Date:8/28/2014)... Aug. 28, 2014 Levi & Korsinsky announces ... the United States District Court for the District of ... who purchased Galectin Therapeutics Inc. ("Galectin" or the "Company") ... 28, 2014. For more information, click here: ... during the Class Period the Company violated federal securities ...
(Date:8/28/2014)... CHARLOTTE, N.C. , Aug. 28, 2014 /PRNewswire/ ... innovation marketplace, today announced a worldwide search for ... of the senior population.  Promising ideas uncovered through ... presented to leading medical device manufacturers and healthcare ... to improve the lives of individuals age 65 ...
Breaking Medicine Technology:New Infographic Published - Overview of Medtech & Life Sciences Industry in San Diego 2SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. and Its Board of Directors and a Lead Plaintiff Deadline of September 29, 2014 -- GALT 2Edison Nation Medical Launches Open Innovation Search to Uncover Innovative Senior Care Products 2Edison Nation Medical Launches Open Innovation Search to Uncover Innovative Senior Care Products 3
... BEVERLY, Mass.--(BUSINESS WIRE)--Apr 10, 2007 - Inotek,Pharmaceuticals Corporation ... preclinical animal data showing that the,administration of a ... on the survival of certain brain,cells following a ... the,repair of damaged DNA via the activation and ...
... study appearing in the March,22 New England Journal ... Healths National Institute of Arthritis and,Musculoskeletal and Skin ... gene and the inflammatory skin,condition vitiligo, as well ... is a chronic condition in which melanocytes (the ...
Cached Medicine Technology:Inotek Pharmaceuticals Announces Publication of Animal Data from,Study of PARP Inhibition as Potential Preventative of Brain Injury,Following Stroke 2Inotek Pharmaceuticals Announces Publication of Animal Data from,Study of PARP Inhibition as Potential Preventative of Brain Injury,Following Stroke 3Scientists Implicate Gene in Vitiligo and Other Autoimmune Diseases 2Scientists Implicate Gene in Vitiligo and Other Autoimmune Diseases 3
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 10.0 mm and length 10 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 8.0 mm and length 7.5 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 10.0 mm and length 12 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 11.0 mm and length 10 mm....
Medicine Products: